Nnukwu ọrịa leukemia Lymphoblastic (T-ALL) -08

Yesheng si Fujian kwuru, "Ọ bụrụ na m maara banyere CAR-T na Ludaopei, agara m abịa na mbụ."

Na Septemba 2017, Yesheng mepụtara rashes ihu, nke ji nwayọọ nwayọọ gbasaa ma jikọta na patches. Ka ọ na-erule February 28, 2018, nyocha ụmị ọkpụkpụ gosipụtara "nnukwu ọrịa leukemia T-cell lymphoblastic" mgbe ọtụtụ usoro ọgwụgwọ chemotherapy gasịrị, na-eji nlele mpụta na-adịghị mma. Akwụsịla ọgwụ niile na June 2019.

Na Mee 2021, Yesheng gosipụtara ọtụtụ mmadụ na mpaghara pharyngeal ọnụ yana ọnụ ọnụ ọnụ olu. Nyochaa ụmị ọkpụkpụ gosipụtara nlọghachi azụ nke leukemia zuru oke. Na Mee 28, e zigara Yesheng na Ngalaba Hematology nke Abụọ nke ụlọ ọgwụ Ludaopei maka nnabata. Mgbe nyochachara nke ọma, e degharịrị nchoputa ahụ ka ọ bụrụ "nnukwu leukemia (T/myeloid biphenotypic)."

Otu usoro ọgwụgwọ chemotherapy emeghị ka mgbaghara dị na ụmị ọkpụkpụ. Na Julaị 27, Yesheng nwetara infusion cell CD7 CAR-T, sochiri kemoterapi jikọtara ya na autologous CD7 CAR-T cell therapy. Ụbọchị iri na ise mgbe infusion gasịrị, nyocha nke ụmị ọkpụkpụ gosipụtara ọrịa na-adịghị mma, yana mmeghachi omume cytokine release syndrome (CRS) ọkwa 1 na enweghị usoro nhụjuanya nke etiti.